Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Desmetramadol a safer, more effective analgesic than tramadol

19 Oct 2019
Healthcare providers to educate the public and promote awareness of the consequences of paracetamol overdose

Desmetramadol is able to provide the analgesic benefits of tramadol without the associated metabolic liabilities, according to a recent series of trials.

The study involved two consecutive randomized, double-blind, three-period cross-over, placebo- and active comparator-controlled trials. Researchers randomly assigned 103 healthy participants to receive 50 mg tramadol and 20 mg desmetramadol either with (trial A; n=43; mean age, 28.4±8.0 years; 100 percent male) or without (trial B; n=60; mean age, 28.0±6.8 years; 70 percent male) cotreatment with paroxetine.

In trial A, participants treated with tramadol (mean change, –0.46±0.19; p=0.022) and desmetramadol (mean change, –0.60±0.15; p=0.0005) exhibited significant decreases in average cold-induced pain perception at 30 seconds relative to placebo controls. No significant differences were reported when the two active treatments were compared against each other (p=0.47).

In the male subgroup of trial B, tramadol failed to produce significantly better analgesia relative to placebo (p=0.90), while desmetramadol significantly outperformed both tramadol (p=0.003) and placebo (p=0.036).

Moreover, in the presence of paroxetine, desmetramadol provided 44-percent longer pain tolerance duration relative to placebo than did tramadol.

In trial A, tramadol and desmetramadol showed comparable safety profiles. Cotreatment with paroxetine seemed to result in fewer adverse events.

“Desmetramadol thus obviates the metabolic liabilities of tramadol while preserving its safety profile, because it does not rely on the activity of CYP enzymes for its activity,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.